108 related articles for article (PubMed ID: 26011351)
1. Expression of FHIT, p16, p53 and EGFR as prognostic markers in thyroid tumors of uncertain malignant potential.
Koc M; Aktimur R; Kagan Gokakin A; Atabey M; Koyuncu A; Elagoz S; Topcu O
J BUON; 2015; 20(2):567-72. PubMed ID: 26011351
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis.
Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M
Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
4. Correlations of breast cancer FHIT gene with the incidence and prognosis of breast cancer.
Fu Y; Shan X; Song W; Xu K; Jiao C; Zhang Q
J BUON; 2019; 24(1):40-47. PubMed ID: 30941950
[TBL] [Abstract][Full Text] [Related]
5. p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy.
Gilbert DC; Williams A; Allan K; Stokoe J; Jackson T; Linsdall S; Bailey CM; Summers J
Radiother Oncol; 2013 Oct; 109(1):146-51. PubMed ID: 24021343
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma.
Lee YM; Lee JB
J Int Med Res; 2013 Jun; 41(3):825-34. PubMed ID: 23569038
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of p16 and p53 expression in oropharyngeal squamous cell carcinomas.
Shinohara S; Kikuchi M; Tona R; Kanazawa Y; Kishimoto I; Harada H; Imai Y; Usami Y
Jpn J Clin Oncol; 2014 Mar; 44(3):232-40. PubMed ID: 24470584
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53, p16, cyclin D1, epidermal growth factor receptor and Notch1 in patients with temporal bone squamous cell carcinoma.
Morita S; Nakamaru Y; Homma A; Yasukawa S; Hatakeyama H; Sakashita T; Kano S; Fukuda A; Fukuda S
Int J Clin Oncol; 2017 Feb; 22(1):181-189. PubMed ID: 27488595
[TBL] [Abstract][Full Text] [Related]
10. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage.
Chen BK; Ohtsuki Y; Furihata M; Takeuchi T; Iwata J; Liang SB; Sonobe H
Int J Oncol; 1999 Nov; 15(5):893-8. PubMed ID: 10536170
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of p16, p53, epidermal growth factor receptor, and human papillomavirus in oropharyngeal cancer in a betel nut-chewing area.
Al-Swiahb JN; Huang CC; Fang FM; Chuang HC; Huang HY; Luo SD; Chen CH; Chen CM; Chien CY
Arch Otolaryngol Head Neck Surg; 2010 May; 136(5):502-8. PubMed ID: 20479383
[TBL] [Abstract][Full Text] [Related]
12. Combined cytoplasmic and membranous EGFR and p53 overexpression is a poor prognostic marker in early stage oral squamous cell carcinoma.
Monteiro LS; Diniz-Freitas M; Garcia-Caballero T; Warnakulasuriya S; Forteza J; Fraga M
J Oral Pathol Med; 2012 Aug; 41(7):559-67. PubMed ID: 22417132
[TBL] [Abstract][Full Text] [Related]
13. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials.
Lassen P; Overgaard J; Eriksen JG
Radiother Oncol; 2013 Sep; 108(3):489-94. PubMed ID: 24060179
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study.
Resnick MB; Routhier J; Konkin T; Sabo E; Pricolo VE
Clin Cancer Res; 2004 May; 10(9):3069-75. PubMed ID: 15131045
[TBL] [Abstract][Full Text] [Related]
15. The prognostic implication of the expression of EGFR, p53, cyclin D1, Bcl-2 and p16 in primary locally advanced oral squamous cell carcinoma cases: a tissue microarray study.
Solomon MC; Vidyasagar MS; Fernandes D; Guddattu V; Mathew M; Shergill AK; Carnelio S; Chandrashekar C
Med Oncol; 2016 Dec; 33(12):138. PubMed ID: 27817107
[TBL] [Abstract][Full Text] [Related]
16. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases.
Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M
Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997
[TBL] [Abstract][Full Text] [Related]
17. Comparing Clinicopathologic and Radiographic Findings Between TT-UMP, Classical, and Non-Encapsulated Follicular Variants of Papillary Thyroid Carcinomas.
Baser H; Topaloglu O; Tam AA; Alkan A; Kilicarslan A; Ersoy R; Cakir B
Endocr Pathol; 2016 Sep; 27(3):233-42. PubMed ID: 27256097
[TBL] [Abstract][Full Text] [Related]
18. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
19. p53, p16 and Fhit proteins expressions in chronic esophagitis and Chagas disease.
Bellini MF; Leite KR; Cury PM; Silva AE
Anticancer Res; 2008; 28(6A):3793-9. PubMed ID: 19189666
[TBL] [Abstract][Full Text] [Related]
20. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
